What the trial was testing
The trial enrolled 25 patients with type 1 diabetes. The study was sponsored by Oregon Health and Science University and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
The AI pump systems kept blood sugar in a healthy range over 70% of the time.
The Lancet. Digital health · 2023 · NCT04771403
These findings — that both AI pump systems kept blood sugar levels in the target range most of the time — were published in the The Lancet. Digital health and represent the headline result of the study.
Researchers tracked outcomes across 25 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with type 1 diabetes, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This was an early-stage study testing experimental insulin pump systems that connect to smartwatches. These specific systems are not yet FDA-approved or available to patients. If you have type 1 diabetes and struggle with blood sugar during exercise, ask your doctor about currently approved automated insulin delivery systems and whether any trials with exercise features are recruiting.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open type 1 diabetes trials
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. There is evidence that α-cell proglucagon processing is subject to paracrine regulation by the β-cell3. It is unclear if the effects of GLP1R agonism on islet GLP-1 differ in Type 1 diabetes (T1DM) compared to T2DM. This experiment will examine the effect of glycemic control ± a GLP1R agonist on islet GLP-1 in people with (T2DM) and without (T1DM) β-cells.
Type 1 Diabetes and Obstructive Sleep Apnea
The purpose of the study is to investigate the role of sleep apnea in glycemic dysregulation in adults with Type 1 diabetes.